Sequent Extended Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFundación EPIC
About this trial
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Sequent Please Neo to meet EU Medical Device regulation (MDR) requirements in all the consecutive patients treated with Sequent Please Neo.
Eligibility criteria
Qualifiers
Patients treated with Sequent please neo according to routine hospital practice and following instruction for use.
Informed Consent Signed.
Disqualifiers
Patient life expectancy less than 12 months.
Contraindication for antiplatelet therapy.
Not meet inclusion criteria.
Trial design
Treatments tested in this trial
- Sequent Please Neo
Treatment groups
2,028 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov